ReviewBiomarkers in cancer2016
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.
Review in Biomarkers in cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.International journal of radiation oncology, biology, physics · 2017Trial
- Population-Level Resources and Costs Associated with Low-Risk Prostate Cancer Patients on Active Surveillance.Cancers · 2026Article
- LMNB2 promotes prostate cancer progression and epithelial-mesenchymal transition via the Wnt/β-catenin pathway.Discover oncology · 2026Article
- Review
- Association of absolute amount of pattern 4 disease on prostate biopsy with oncologic outcomes in intermediate-risk prostate cancer A systematic review.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Review
- Article
- Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models.European radiology · 2024Article
- Article
- Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects.Human molecular genetics · 2023Article
- Knockdown of KIF15 suppresses proliferation of prostate cancer cells and induces apoptosis through PI3K/Akt signaling pathway.Cell death discovery · 2023Article
- Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.NPJ digital medicine · 2022Article
- A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.Saudi journal of biological sciences · 2022Review
- A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy.Theranostics · 2022Article
- Emerging Proteins in CRPC: Functional Roles and Clinical Implications.Frontiers in oncology · 2022Review
- Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA Database.Genes · 2021Article
- Immunophenotype Rearrangement in Response to Tumor Excision May Be Related to the Risk of Biochemical Recurrence in Prostate Cancer Patients.Journal of clinical medicine · 2021Article
- Anti-tumor activities ofJournal of ginseng research · 2021Article
- Article
- The role of the voltage-gated potassium channel, Kv2.1 in prostate cancer cell migration.BMB reports · 2021Article
- Cardiac, Hepatic and Renal Dysfunction and IL-18 Polymorphism in Breast, Colorectal, and Prostate Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PC) is the second most common form of cancer in men worldwide. Biomarkers have emerged as essential tools for treatment and assessment since the variability of disease behavior, the cost and diversity of treatments, and the related impairment of quality of life have given rise to a need for a personalized approach. High-throughput technology platforms in proteomics and genomics have accelerated the development of biomarkers. Furthermore, recent successes of several new agents in PC, including immunotherapy, have stimulated the search for predictors of response and resistance and have improved the understanding of the biological mechanisms at work. This review provides an overview of currently established biomarkers in PC, as well as a selection of the most promising biomarkers within these particular fields of development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.